Mean Platelet Volume Predicts Short-term Prognosis in Young Patients with St-segment Elevation Myocardial Infarction

Open access


Background: Acute ST-elevation myocardial infarction (STEMI) is an uncommon diagnosis in patients less than 40 years of age. Over the last two decades, there is an increase in the frequency of cardiovascular events among young adults. However, at present there is only limited clinical data on the clinical characteristics and outcomes of STEMI in young patients who were treated with primary percutaneous coronary intervention (pPCI). Plaque erosion is the underlying pathological mechanism leading to STEMI in the vast majority of young adults. Thrombi that complicate superficial erosion seem more platelet-rich than the fibrinous clots precipitated by plaque rupture. Mean platelet volume (MPV) is recognized as a marker of the platelet activation process and may be a better indicator of short-term prognosis than the inflammatory markers in young patients with STEMI. Therefore, we aimed to investigate clinical and angiographic characteristics, risk factors and the independent value of MPV on predicting short-term major adverse cardiovascular events (MACEs) in young adults with STEMI. Methods: A total of 349 patients aged 40 years or younger who underwent pPCI at our center between 2010–2015 with the diagnosis of STEMI were retrospectively analyzed. Results: The mean age of the patients was 36.4 ± 3.6 years and 90% of them were men. Smoking was by far the most frequent cardiovascular risk factor. MACEs were observed in 23 patients (6.6%), and according to the multivariate regression analysis, Killip IIIIV (OR 7.52, 95% CI 1.25–45.24, p = 0.03), lower admission SBP (OR 0.94, 95% CI 0.90–0.98, p <0.01) and increased MPV (OR 1.67, 95% CI 1.05–2.67, p = 0.03) were found to be independently correlated with MACE in the study population. Conclusion: Our results indicate that MPV is an independent predictor of MACEs at the short-term follow-up in young patients with STEMI undergoing pPCI. Accordingly, we suggested that MPV, a marker of platelet activation, could play a significant role in predicting clinical evolution in young patients with STEMI.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Mensah GA Wei GS Sorlie PD et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res. 2017;120:366-380. doi: 10.1161/CIRCRESAHA.116.309115.

  • 2. GBD 2015 Mortality and Causes of Death Collaborators. Global regional and national life expectancy all-cause mortality and cause-specific mortality for 249 causes of death 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459-1544. doi: 10.1016/S0140-6736(16)31012-1.

  • 3. Roth GA Huffman MD Moran AE et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132:1667-1678. doi: 10.1161/CIRCULATIONAHA.114.008720.

  • 4. Bajaj S Shamoon F Gupta N et al. Acute ST-segment elevation myocardial infarction in young adults: who is at risk? Coron Artery Dis. 2011;22:238-244. doi: 10.1097/MCA.0b013e3283452e7f.

  • 5. Lautamaki A Airaksinen KEJ Kiviniemi T et al. Prognosis and disease progression in patients under 50 years old undergoing PCI: The CRAGS (Coronary aRtery diseAse in younG adultS) study. Atherosclerosis. 2014;235:483-487. doi: 10.1016/j.atherosclerosis.2014.05.953.

  • 6. Jinnouchi H Sakakura K Wada H et al. Clinical features of myocardial infarction in young Japanese patients. Int Heart J. 2013;54:123-128.

  • 7. Oliveira A Barros H Maciel MJ Lopes C. Tobacco smoking and acute myocardial infarction in young adults: a population-based case-control study. Prev Med. 2007;44:311-316. doi: 10.1016/j.ypmed.2006.12.002.

  • 8. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Patients. Third report of National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Patients (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.

  • 9. Chung EH Curran PJ Sivasankaran S et al. Prevalence of metabolic syndrome in patients ≤45 years of age with acute myocardial infarction having percutaneous coronary intervention. Am J Cardiol. 2007;100:1052-1055. doi: 10.1016/j.amjcard.2007.05.028.

  • 10. Singh A Collins B Qamar A et al. Study of young patients with myocardial infarction: Design and rationale of the YOUNG-MI Registry. Clin Cardiol. 2017;40:955-961. doi: 10.1002/clc.22774.

  • 11. Konishi H Miyauchi K Kasai T Tsuboi S Ogita M Naito R. Long-term prognosis and clinical characteristics of young adults (≤40 years old) who underwent percutaneous coronary intervention. J Cardiol. 2014;64:171-174. doi: 10.1016/j.jjcc.2013.12.005.

  • 12. Meliga E De Benedictis M Gagnor A Belli R Scrocca I Lombardi P. Long-term outcomes of percutaneous coronary interventions with stent implantation in patients ≤40 years old. Am J Cardiol. 2012;109:1717-1721. doi: 10.1016/j.amjcard.2012.01.400.

  • 13. Berger JS Eraso LH Xie D Sha D Mohler ER 3rd. Mean platelet volume and prevalence of peripheral artery disease the National Health and Nutrition Examination Survey 1999-2004. Atherosclerosis 2010;213:586-591. doi: 10.1016/j.atherosclerosis.2010.09.010.

  • 14. Pizzulli L Yang A Martin JF Luderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J. 1998;19:80-84. doi: 10.1053/euhj.1997.0747.

  • 15. Varol E Aksoy F Özaydın M Erdoğan D Doğan A. Relationship between mean platelet volume and mitral annular calcification. Blood Coagul Fibrinolysis. 2013;24:189-193. doi: 10.1097/MBC.0b013e32835b7296.

  • 16. Huczek Z Kochman J Filipak KJ et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;46:284-290. doi: 10.1016/j.jacc.2005.03.065.

  • 17. Tomasz R Aleksandra J Jakub F et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. Cardiol J. 2013;20:491-498. doi: 10.5603/CJ.2013.0134.

  • 18. Levey AS Stevens LA Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.

  • 19. Killip T Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457-464.

  • 20. Sianos G Papafaklis MI Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010;22:6B-14B.

  • 21. Kirma C Izgi A Dundar C et al. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J. 2008;72:716-721.

  • 22. Cheitlin MD Armstrong WF Aurigemma GP et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography). J Am Coll Cardiol. 2003;42:954-970.

  • 23. Braunwald E. Coronary plaque erosion: recognition and management. JACC Cardiovasc Imaging. 2013;6:288-289. doi: 10.1016/j.jcmg.2013.01.003.

  • 24. Kolodgie FD Burke AP Farb A et al. Plaque erosion. In: Virmani R Narula J Leon MB Willerson JT editors. The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management. Boston MA: Blackwell Publishing 2007; p. 60-76.

  • 25. Dai J Xing L Jia H et al. In vivo predictors of plaque erosion in patients with ST-segment elevation myocardial infarction: a clinical angiographical and intravascular optical coherence tomography study. Eur Heart J. 2018;39:2077-2085. doi: 10.1093/eurheartj/ehy101.

  • 26. Mincu RI Jánosi RA Vinereanu D Rassaf T Totzeck M. Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis. Sci Rep. 2017;7:41530. doi: 10.1038/srep41530.

  • 27. Sawant AC Adhikari P Narra SR Srivatsa SS Mills PK Srivatsa SS. Neutrophil to lymphocyte ratio predicts short-and long-term mortality following revascularization therapy for ST elevation myocardial infarction. Cardiol J. 2014;21:500-508. doi: 10.5603/CJ.a2013.0148.

  • 28. Park JJ Jang HJ Oh IY et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111:636-642. doi: 10.1016/j.amjcard.2012.11.012.

  • 29. Machado GP Araujo GN Carpes CK et al. Comparison of neutrophil-to-lymphocyte ratio and mean platelet volume in the prediction of adverse events after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Atherosclerosis. 2018;274:212-217. doi: 10.1016/j.atherosclerosis.2018.05.022.

  • 30. Toprak C Tabakci MM Simsek Z Arslantas U Durmus HI Ocal L. Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Postepy Kardiol Interwencyjnej. 2015;11:288-297. doi: 10.5114/pwki.2015.55599.

  • 31. Ozcan Cetin EH Cetin MS Aras D et al. Platelet to Lymphocyte Ratio as a Prognostic Marker of In-Hospital and Long-Term Major Adverse Cardiovascular Events in ST-Segment Elevation Myocardial Infarction. Angiology. 2016;67:336-345. doi: 10.1177/0003319715591751.

  • 32. Karataş MB Çanga Y Özcan KS et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emerg Med. 2016;34:240-244. doi: 10.1016/j.ajem.2015.10.049.

  • 33. Libby P Pasterkamp G Crea F Jang IK. Reassessing the Mechanisms of Acute Coronary Syndromes The “Vulnerable Plaque” and Superficial Erosion. Circ Res. 2019;124:150-160.

  • 34. Campbell IC Suever JD Timmins LH et al. Biomechanics and inflammation in atherosclerotic plaque erosion and plaque rupture: implications for cardiovascular events in women. PLoS One. 2014;9:e111785. doi: 10.1371/journal.pone.0111785.

  • 35. Niccoli G Montone RA Cataneo L et al. Morphological-biohumoral correlations in acute coronary syndromes: pathogenetic implications. Int J Cardiol. 2014;171:463-466. doi: 10.1016/j.ijcard.2013.12.238.

  • 36. Ferrante G Nakano M Prati F et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation. 2010;122:2505-2513. doi: 10.1161/CIRCULATIONAHA.110.955302.

  • 37. Saia F Komukai K Capodanno D Sirbu V Musumeci G Boccuzzi G. Eroded Versus Ruptured Plaques at the Culprit Site of STEMI: In Vivo Pathophysiological Features and Response to Primary PCI. JACC Cardiovasc Imaging. 2015;8:566-575. doi: 10.1016/j.jcmg.2015.01.018.

  • 38. Sianos G Papafaklis MI Daemen J. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573-583. doi: 10.1016/j.jacc.2007.04.059.

  • 39. Kamath S Blann AD Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561-1571. doi: 10.1053/euhj.2000.2515.

  • 40. Grove EL Hvas AM Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101:151-156.

  • 41. Funck-Jensen KL Dalsgaard J Grove EL Hvas AM Kristensen SD. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. Platelets. 2013;24:528-537. doi: 10.3109/09537104.2012.738838.

  • 42. Tschoepe D Roesen P Esser J et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991;17:433-438. doi: 10.1055/s-2007-1002650.

  • 43. Debili N Masse JM Katz A Guichard J Breton-Gorius J Vainchenker W. Effects of the recombinant hematopoietic growth factors interleukin-3 interleukin-6 stem cell factor and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood. 1993;82:84-95.

  • 44. Tekbas E Kara AF Ariturk Z et al. Mean platelet volume in predicting short- and long-term morbidity and mortality in patients with or without ST-segment elevation myocardial infarction. Scand J Clin Lab Invest. 2011;71:613-619. doi: 10.3109/00365513.2011.599416.

  • 45. Ranjith MP DivyaRaj R Mathew D George B Krishnan MN. Mean platelet volume and cardiovascular outcomes in acute myocardial infarction. Heart Asia. 2016;8:16-20. doi: 10.1136/heartasia-2015-010696.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 123 123 24
PDF Downloads 77 77 23